InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（12 笔）
内部人交易记录
其他已披露买入
0
已披露卖出
12
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the complete record of transactions filed by Sandrock Alfred, Responsable de la Recherche et Développement. Insider active across 2 companies, notably BIOGEN INC.. Cumulatively, 18 disclosures have been published. Breakdown: 0 buy · 12 sells. Total volume traded: €3.3m. History available since 7 June 2021. The latest transaction was disclosed on 2 April 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Sandrock Alfred
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报18 总计
11,511 股@ US$3.878.6% 占其流量Common StockSEC:0001104659-26-039691:0
14,197 股@ US$3.798.1% 占其流量Common StockSEC:0001104659-26-020181:0
11,732 股@ US$3.416.0% 占其流量Common StockSEC:0001104659-26-018126:0
12,192 股@ US$3.786.9% 占其流量Common StockSEC:0001104659-26-013414:0
86,250 股0Common StockSEC:0001104659-26-012672:0
10,885 股@ US$3.438.4% 占其流量Common StockSEC:0001104659-25-032202:0
11,702 股@ US$4.2411.7% 占其流量Common StockSEC:0001104659-25-016520:0
16,644 股@ US$4.4517.6% 占其流量Common StockSEC:0001104659-25-012196:0
12,115 股@ US$9.8627.2% 占其流量Common StockSEC:0001104659-24-043104:0
13,033 股@ US$7.4622.0% 占其流量Common StockSEC:0001104659-24-026561:0
130,000 股0Common StockSEC:0001104659-24-024982:0
7,437 股@ US$7.8313.1% 占其流量Common StockSEC:0001104659-23-042230:0
120,000 股0Common StockSEC:0001104659-23-024418:0
100,000 股0Common StockSEC:0001104659-22-037149:0
7,672 股@ US$440.00100.0% 占其流量Common StockSEC:0001127602-21-019553:0
1,278 股Common StockSEC:0001127602-16-040394:0
426 股Common StockSEC:0001127602-16-040394:1
852 股Common StockSEC:0001127602-16-040394:2
18 条申报中的 18 条
About Sandrock Alfred
Sandrock Alfred is Head of Research & Development. He has filed 18 forms in total, and across the 18 sampled filings between 2016-02-10 and 2026-04-03, the recorded transactions are sales for a total of EUR 3333026. The companies mentioned in these filings are Voyager Therapeutics, Inc. and BIOGEN INC., including a sale of EUR 2768395.261659232 at BIOGEN INC. on 2021-06-09.
